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Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services
and management of hepatitis B
When taken properly, Tenofovir-based oral preexposure
prophylaxis (PrEP)has beenproven tobe efficient to prevent
HIVacquisition [1–5]. Since 2015, PrEP is recommended
by theWHO for populations at ‘substantial risk’ of HIV [6].
However,WHOpoints out the need for additional research
on PrEP in ‘real life’ on questions such as demand creation
for oral PrEP; best delivery models in different contexts and
for different populations; social and behavioral impact of
PrEP; or integrationof PrEP serviceswith other services [6].
Transitioning fromefficacy trials to implementation requires
to adapt interventions. Preliminary research (ANRS 12361
PrEP-CI [7]) has been conducted in Coˆte d’Ivoire (CI) in
collaboration with community non-governmental orga-
nizations to explore relevance and feasibility of implement-
ing a PrEP program among female sex workers, one of the
most exposed populations countrywide (estimated HIV
prevalence: 29% [8]). The following observations emerged
from that collective work.
All efficacyPrEP trials provided a rangeof sexual healthcare
services in addition to PrEP drugs [9–11]. Such services
appeared essential for any PrEP program. By design, they
were conditional to PrEP use. However, regardless of their
interest in using PrEP, female sex workers interviewed in
Coˆte d’Ivoire, and more broadly key populations
worldwide [12–16], have many unmet sexual and
reproductive health needs: sexually transmitted infections
screening and care, contraception and birth control,
menstrual management, addictions and risky behaviors. . .
When transitioning to real life, we should not reproduce
the service model of efficacy PrEP trials, that is a PrEP
program with additional services. Instead, a paradigm shift
toward a patient-centered approach should be preferred,
that is offering sexual and reproductive health services in
which PrEP is an option but not mandatory.
In Western and Central Africa, the prevalence of hepatitis
B is relatively high [17]. In Cote d’Ivoire, more than 11%
of new blood donors were positive for hepatitis B surface
antigen in 2008–2012 [18]. Tenofovir is also used for
hepatitis B treatment. But, currently, treatment is not free
for monoinfected hepatitis B patients, whereas it is
covered by AIDS programs for HIV-hepatitis B coin-
fected patients. In such context, it would be ethically
unacceptable to provide free HIV PrEP without taking
into account patients in needs of hepatitis B treatment.
Actually, for those patients, offering Tenofovir-based HIV
PrEP constitutes an opportunity to simultaneously treat
their hepatitis B. It requires to integrate WHO
recommendations on hepatitis B [19] within PrEP
guidelines [20], possibly to simplify hepatitis B care
algorithms and to allow hepatitis B care in decentralized
sexual health clinics and not only in hospital services.
Most efficacy PrEP trials excluded hepatitis B patients.
Additional clinical research exploring interactions
between HIV PrEP and hepatitis B treatment, in
particular the risk of flare if PrEP is stopped, is required.
PrEP programs could be built on the existing community
services for HIV care and treatment. Providing services for
HIV positives and HIV negatives within the same clinics
could be a way of minimizing the stigma associated with
entry and retention into HIV care. In addition, HIV
patients have unmet sexual and reproductive health needs
aswell. Integrating services together and transformingHIV
clinics into sexual health clinics could lead to many health
outcomes improvements and also to possible cost sharing
and savings.
So far, the focus of HIV programs has mainly been on
reaching individuals never tested for HIV, identifying new
positives and linking them to HIV care and treatment.
Transitioning PrEP from trials to implementation con-
stitutes an opportunity for developing people-centered
approaches integrating all sexual and reproductive health
services together, including hepatitis B. It is crucial to avoid
a silo-based perspective in which services are separated
from each other. Moving from HIV care clinics to sexual
health clinicswould allow to globally improve the health of
key populations and their partners, beyond HIVoutcomes
alone. To ensure the success of new prevention programs,
we have to take the next step forward. Beyond biomedical
innovations, innovations in terms of intervention imple-
mentation, delivery models and public health policies are
urgently required [21], in particular inWestern andCentral
Africa [22]. Scaling-up PrEP is a key moment. We should
not miss out on this opportunity.
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John Cunningham virus large T antigen detection in brain biopsy of an HIV-infected patient with
glioblastoma multiforme: more than a coincidental finding
Double-stranded DNA of John Cunningham virus (JCV)
contains the early genes region, the late genes region, and
the noncoding regulatory region. The large T antigen
(LT-Ag), small T antigen, and T proteins encoded by the
first region play a critical role in the transformation,
genetic regulation, and replication of the virus. The late
genes region produces the capsid proteins VP1, VP2, and
VP3 in addition to the accessory Agno protein [1,2].
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